Visudyne: profile and news
QLT's Visudyne Q1sales drop in $106.8M US, down 13.7 per cent from ... Apr 24, 2006
TSX:QLT) said Monday that global sales of Visudyne, its main ... The company has said it expects Visudyne sales in 2006 to be between $370 million to $400 million. ... - Canada.com,
QLT's Visudyne sales hit hard by rivals Apr 25, 2006
...saw sales of its Visudyne drug, a treatment for the leading cause of blindness in adults, tumble 14 per cent in the first quarter, reigniting weakness in its ... - Globe and Mail,
QLT announces Visudyne(R) sales for first quarter of 2006 Apr 23, 2006
...(NASDAQ: QLTI; TSX: QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of approximately US$106.8 million ... - MSN Money
UPDATE 1-QLT 1st-qtr profit dips on lower Visudyne sales Apr 27, 2006
QLT.TO: Quote, Profile, Research) reported a lower first-quarter profit on Thursday hurt by weaker sales of its key Visudyne product and higher legal expenses. ... - Reuters
Visudyne Q1 sales down 13.7%, QLT reports Apr 24, 2006
...reported Monday that global sales of the eye drug Visudyne, its main source of revenue, dropped by 13.7 per cent to $106.8 million US in the first quarter from ... - CBC.ca,
(PRN) - QLT announces Visudyne(R) sales for first quarter of 2006 ... Apr 23, 2006
...(PRN) - FUN Technologies signs online gaming agreement with skysports.com, British Sky Broadcasting Group's online sports channel ... [+. ... - Bolsamania.com,
QLT reports lower first quarter sales of Visudyne Apr 25, 2006
...on Monday reported a drop of almost 14 per cent in its first-quarter global sales of Visudyne, a treatment for age-related macular degeneration that is facing ... - Vancouver Sun (subscription),
QLT Announces Visudyne Sales for First Quarter of 2006 Apr 24, 2006
...today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of approximately US$106.8 million for the quarter ended March ... - PharmaLive.com (press release),
QLT announces Visudyne(R) sales for first quarter of 2006 Apr 24, 2006
VANCOUVER, April 24 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product ... - CNW Telbec (Communiqués de presse),
QLT to focus on new products May 10, 2006
VANCOUVER -- Facing tumbling sales of its flagship blindness drug Visudyne , QLT Inc. is looking to other products in its pipeline ... - Globe and Mail,
QLT announces Visudyne(R) sales for first quarter of 2006 Apr 23, 2006
...(NASDAQ: QLTI - News; TSX: QLT - News) today reported that Novartis AG announced global sales of QLT's Visudyne® (verteporfin) product of approximately US ... - Yahoo! News (press release)
QLT announces Q1 results for 2006 and provides R&D guidance Apr 27, 2006
Visudyne® worldwide sales for the first quarter were $106.8 million, a decrease of 13.7% over the first quarter of 2005. Visudyne ... - Yahoo! News (press release)
QLT announces Q1 results for 2006 and provides R&D guidance Apr 27, 2006
2006 Q1 Results Sales Visudyne(R) worldwide sales for the first quarter were $106.8 million, a decrease of 13.7% over the first quarter of 2005. ... - PR Newswire (press release),
QLT Inc. Q1 profit drops to $12.1 million US from $15.3 million as ... Apr 27, 2006
...year. QLT said its profit decline was primarily due to a reduction in sales of its Visudyne eye drug and higher legal expenses. ... - CBC News,
QLT reports lower profits Apr 27, 2006
...last year. QLT said its profit decline was primarily due to a reduction in sales of its flagship Visudyne eye drug. Higher legal ... - Ottawa Business Journal,
Sales of QLT eye treatment hurt by rival drug Apr 24, 2006
NEW YORK (Reuters) - QLT Inc. (QLT.TO: Quote) (QLTI.O: Quote) said on Monday said first-quarter global sales of Visudyne, its treatment for the leading cause ... - Reuters Canada,
Q1 2006 QLT Inc. Earnings Conference Call - Research and Markets ... Apr 27, 2006
Management reported 1Q06 diluted net income per share of $0.13, down from $0.16 in 1Q05, primarily due to reduced Visudyne sales and higher legal expenses. ... - Business Wire (press release),
QLT announces TSX approval of second year of two-year share ... May 7, 2006
...of innovative drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®. ... - Yahoo! News (press release)
(PZ) Novartis Delivers Strong Start to 2006 in First Quarter with ... Apr 24, 2006
Partially offsetting this performance were lower sales of Elidel, affected by a change in prescribing information, and Visudyne, which has faced increased ... - Houston Chronicle,
QLT reports slower sales, lower profits Apr 28, 2006
...reported a lower profit in the first quarter compared with a year ago, as sales of both its main source of revenue, Visudyne, and its treatment for prostate ... - Vancouver Sun (subscription),
Stocks lower as energy and gold prices decline, investors await ... Apr 24, 2006
QLT Inc.'s (TSX:QLT) shares were off 21 cents to $9.16 after it said global Visudyne sales dropped 13.7 per cent in the first quarter, to $106.8 million US. ... - CBC News,
Novartis Q1 net beats expectations on underlying growth ... Apr 23, 2006
Gleevec, Femara and Exjade. The strong performance was partially offset by weaker sales for Elidel and Visudyne. Net sales in Europe ... - Forbes
Investors eye dollar, oil Apr 24, 2006
...in March. QLT Inc. reported global Visudyne sales dropped 13.7 per cent in the first quarter, to $106.8-million (US). The eye drug ... - Globe and Mail,
Novartis Q1 Profit Climbs On Sales Growth, Acquisition; Announces ... Apr 24, 2006
...offset by lower sales of eczema drug Elidel due to a change in prescribing information, and age-related macular degeneration treatment Visudyne due to ... - Trading Markets,
(PRN) - Neuropharma Introduces in Clinical Trials its First ... Apr 24, 2006
...(PRN) - Dana Corporation to Feature Fuel-Cell Technologies at Hannover Fair ... [+. PRN) - QLT announces Visudyne(R) sales for first quarter of 2006 ... [+. ... - Bolsamania.com,
Canadian Stocks Linger In Negative Territory - Canadian Commentary Apr 24, 2006
Shares of QLT (QLT.TO) are also seeing significant weakness after the drug maker said first quarter sales of its Visudyne product fell 13.7 percent year-over ... - Trading Markets,
